115 related articles for article (PubMed ID: 3752939)
1. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.
Dornish JM; Melvik JE; Pettersen EO
Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cis-dichlorodiammineplatinum (II)-induced cytotoxicity by methylglyoxal.
Dornish JM; Pettersen EO
Anticancer Res; 1989; 9(4):1137-42. PubMed ID: 2817795
[TBL] [Abstract][Full Text] [Related]
3. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
4. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.
Dornish JM; Pettersen EO; Oftebro R; Melvik JE
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1287-93. PubMed ID: 6541584
[TBL] [Abstract][Full Text] [Related]
5. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
6. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
Montine TJ; Borch RF
Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives.
Dornish JM; Pettersen EO
Cancer Lett; 1989 Jul; 46(1):63-8. PubMed ID: 2736510
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro.
Dornish JM; Undheim K; Pettersen EO; Oftebro R; Laland SG
Anticancer Drug Des; 1988 Dec; 3(3):191-8. PubMed ID: 3207466
[TBL] [Abstract][Full Text] [Related]
9. Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-dichlorodiammineplatinum-induced cell inactivation.
Dornish JM; Pettersen EO
Biochem Pharmacol; 1990 Jan; 39(2):309-18. PubMed ID: 2302256
[TBL] [Abstract][Full Text] [Related]
10. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
Waud WR
Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.
Dornish JM; Pettersen EO; Oftebro R
Br J Cancer; 1987 Sep; 56(3):273-8. PubMed ID: 3663475
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
[TBL] [Abstract][Full Text] [Related]
13. In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity.
Melvik JE; Dornish JM; Larsen RO; Børretzen B; Oftebro R; Pettersen EO
Anticancer Res; 1992; 12(1):33-8. PubMed ID: 1567178
[TBL] [Abstract][Full Text] [Related]
14. Protein accumulation in lethally damaged cells after treatment with cis-dichlorodiammineplatinum (II): lack of temporal correlation between drug effect and inhibition of spheroid volume growth.
Nordal AK; Juul NO; Pettersen EO
Anticancer Res; 1992; 12(2):305-11. PubMed ID: 1580548
[TBL] [Abstract][Full Text] [Related]
15. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
Ali-Osman F; Berger MS; Rairkar A; Stein DE
J Cell Biochem; 1994 Jan; 54(1):11-9. PubMed ID: 8126081
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP levels of C6 glioma cells treated with cis-dichlorodiammine platinum (cis-DDP).
Folbergrová J; Lisá V; Drobník J; Mares V
Neoplasma; 1987; 34(1):3-13. PubMed ID: 3031519
[TBL] [Abstract][Full Text] [Related]
17. Effect of cis- and trans-dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo.
Ambrose KR; Lowrey JS
Cancer Res; 1982 May; 42(5):1769-73. PubMed ID: 7039818
[TBL] [Abstract][Full Text] [Related]
18. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
20. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
